Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03188705
PHASE4

CES1 Carriers in the PAPI Study

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1) on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy.

Official title: Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study

Key Details

Gender

All

Age Range

20 Years - Any

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2019-10-14

Completion Date

2020-01-17

Last Updated

2026-07-31

Healthy Volunteers

Yes

Interventions

DRUG

Clopidogrel

Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

DRUG

Aspirin

Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.

Locations (1)

Amish Research Clinic

Lancaster, Pennsylvania, United States